Zou D, et al. - Whether pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) has effectiveness as well as safety in preventing neutropenia during chemoradiotherapy in patients with cervical cancer, was inquired herein. Participants were 60 patients who were pathologically proven as cervical cancer. They were randomly split into two groups at a ratio of 2:1: PEG-modified-rhG-CSF experimental group and control group. It was found that reduction in the incidence of neutropenia as well as improvement in the incidence of delayed chemotherapy cycles can be conferred by PEG-rhG-CSF preventive treatment used in the course of chemoradiotherapy for cervical cancer patients.